Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer

por Gu, Yangchun, He, Huiying, Wang, Mopei
Publicado 2021

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

por Zhang, Yixi, La, Bin, Liang, Baosheng, Gu, Yangchun
Publicado 2021

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort s...

por Gu, Yangchun, Yu, Jinyu, Hu, Haifeng, Zhang, Hua, Cao, Baoshan, Liang, Li
Publicado 2023

Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma

por Guo, Ziwei, Yi, Fumei, Yin, Wencheng, Zhang, Yu, Li, Qian, Gu, Yangchun, Xiao, Yu, Cao, Baoshan, Ma, Liwen, Liang, Li
Publicado 2017

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analys...

por Zou, Zihua, Hao, Xuezhi, Zhang, Cuiying, Li, Haojing, Dong, Guilan, Peng, Yumei, Ma, Kewei, Guo, Ye, Shan, Li, Zhang, Yan, Liang, Li, Gu, Yangchun, Xing, Puyuan, Li, Junling
Publicado 2021

Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor

por LI, Qian, SUN, Tao, ZHANG, Hua, LIU, Wei, XIAO, Yu, SUN, Hongqi, YIN, Wencheng, YAO, Yanhong, GU, Yangchun, LIU, Yan'e, YI, Fumei, WANG, Qiqi, YU, Jinyu, CAO, Baoshan, LIANG, Li
Publicado 2022

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appro...

por Gu, Yangchun, Xu, Yan, Zhuang, Hongqing, Jiang, Weijuan, Zhang, Hua, Li, Xiaofeng, Liu, Yonggang, Ma, Li, Zhao, Dahai, Cheng, Yuan, Yu, Yan, Liu, Ping, Qin, Jianwen, Chen, Xueqin, Gao, Junzhen, Wang, Mengzhao, Liang, Li, Cao, Baoshan
Publicado 2021

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

por Zou, Zihua, Gu, Yangchun, Liang, Li, Hao, Xuezhi, Fan, Chengjuan, Xin, Tao, Zhao, Songchen, Liu, Ziling, Guo, Ye, Ma, Kewei, Li, Haojing, Zhang, Cuiying, Shan, Li, Zhang, Yan, Dong, Guilan, Peng, Yumei, Shen, Fangfang, Song, Xia, Christopoulos, Petros, van der Wekken, Anthonie J., Okuda, Katsuhiro, Ekman, Simon, Xing, Puyuan, Li, Junling
Publicado 2022

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observ...

por Liang, Hongge, Song, Xia, Zhang, Yuhui, Zhang, Shucai, Li, Fang, Fang, Jian, Li, Junling, Liang, Li, Nie, Ligong, Ma, Kewei, Zhang, Liangming, Wang, Xiaohong, Xu, Junjun, Wei, Yanxia, Wang, Jinghui, Song, Qi, Tian, Guangming, Mu, Yuxin, Gu, Yangchun, Yang, Lei, Sun, Ping, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Wang, Mengzhao
Publicado 2019

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

por Shi, Yuequan, Fang, Jian, Zhou, Chengzhi, Liu, Anwen, Wang, Yan, Meng, Qingwei, Ding, Cuimin, Ai, Bin, Gu, Yangchun, Yao, Yu, Sun, Hong, Guo, Hui, Zhang, Cuiying, Song, Xia, Li, Junling, Xu, Bei, Han, Zhiqiang, Song, Meijun, Tang, Tingyu, Chen, Peifeng, Lu, Hongmin, Shui, Yongjie, Lou, Guangyuan, Zhang, Dongming, Liu, Jia, Liu, Xiaoyan, Liu, Xiangning, Gao, Xiaoxing, Zhou, Qing, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Xu, Yan, Wang, Mengzhao
Publicado 2021